Led · Series B · Apr 2026

Nervonik is developing a next-generation peripheral nerve stimulation platform that combines electrical stimulation with advanced sensing to enable more precise, personalized neuromodulation therapies. Its implantable leads have demonstrated the ability to record evoked compound action potentials (ECAPs) and other physiological biomarkers. The company is advancing clinical programs and preparing for commercialization of its PNS system. Recent financing will fund further development of its proprietary sensing capabilities and support commercialization activities. Nervonik is headquartered in Los Angeles, California.

Led · Series A · Jan 2025

Sound Blade Medical develops handheld ultrasound-guided histotripsy technology designed to deliver non-invasive, non-thermal, and non-ionizing mechanical tissue ablation guided by real-time imaging. Its device induces cavitation bubbles with short, high-pressure ultrasound pulses so collapsing bubbles liquefy targeted tissue, which the company says may allow better immune and healing responses and avoid heat-related risks. The company positions histotripsy as offering potentially improved patient outcomes versus open surgery, including less blood loss, fewer complications, reduced recovery time, and decreased infection risk. Founded in 2023 and based in Halifax, Nova Scotia, Sound Blade plans to use new funding to accelerate development and clinical validation, expand its team, and pursue regulatory approvals. The company closed an oversubscribed US $16.5 million Series A to support those efforts. Jeremy Brown, Ph.D., is co-founder and CEO.

Participated · Series B · Oct 2024

ShiraTronics develops a Migraine Therapy System that delivers neurostimulation intended to reduce headache days and attack severity and improve quality of life for chronic migraine patients. The company reported encouraging reductions in headache days, decreased migraine severity, and improved quality-of-life scores in its first-in-human pilot study. ShiraTronics received Breakthrough Device designation from the FDA's CDRH in 2021. It is now running an FDA-approved pivotal trial (RELIEV-CM2), a multi-center, blinded, randomized, sham-controlled study targeting patients who have failed current medical therapies. The company plans to use new funding to support that pivotal trial, pursue FDA premarket approval, and fund the initial commercial launch of its therapy. Rob Binney serves as CEO and is leading the company through these regulatory and commercialization milestones. ShiraTronics is a Brooklyn Park, Minnesota-based private medical device company focused on an innovative therapy for migraine headaches. The company is developing and clinically testing a neuromodulation technology as its core product. ShiraTronics was spun off from NuXcel, an electrical medical device accelerator. The company is led by President and CEO Lynn Elliott and co-founder and Chairman Mudit K. Jain, PhD. It completed an additional $3M Series A, bringing the Series A to $36M, and intends to use the funds to further accelerate its path to market. ShiraTronics is a Minneapolis-based private medical device company developing an innovative neuromodulation approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology. ShiraTronics was seeded in 2019 as a spin-off from NuXcel, a medical device accelerator managed by co-founder Mudit K. Jain, PhD, and Lynn Elliott. Lynn Elliott joined as President and CEO, with Mudit K. Jain serving as co-founder and Chairman of the Board. Prior to the Series A the company was backed by Strategic HealthCare Investment Partners (S.H.I.P.). In October 2019 ShiraTronics completed a $33M Series A financing to advance its clinical development.

Participated · Series D · Aug 2024

HistoSonics develops a non-invasive therapeutic platform based on histotripsy, a focused-ultrasound technology that uses acoustic cavitation to mechanically destroy and liquefy targeted tissue. Its flagship product, the Edison® Histotripsy System, received U.S. FDA De Novo clearance for the destruction of liver tumors and has seen expanding clinical adoption at academic medical centers and health systems. Use of the system outside the liver remains investigational while the company pursues regulatory clearances for additional organs. HistoSonics has submitted a De Novo request to the FDA for kidney tumors and is advancing toward an anticipated FDA submission for pancreatic applications. The company is focused on commercializing the Edison System in the U.S. and select global markets while expanding indications into kidney, pancreas, prostate and other organs. HistoSonics maintains offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN, and was valued at $3.75 billion in its most recent financing.

Participated · Series B · Apr 2024

Miach Orthopaedics develops the Bridge-Enhanced ACL Restoration (BEAR®) Implant, a bio‑engineered product that facilitates healing of torn anterior cruciate ligaments rather than replacing them. The BEAR Implant acts as a bridge between ACL ends, uses a small amount of the patient’s blood to promote healing, and is resorbed as the ligament repairs. It received De Novo FDA approval in December 2020 and is indicated for skeletally mature patients (14+) with a complete ACL rupture and an ACL stump attached to the tibia. The company reports the BEAR Implant has been used to treat nearly 3,000 patients. Miach says the technology is a paradigm shift from ACL reconstruction because it avoids graft harvest or donor tendons and preserves the ACL’s native attachments. Current priorities include U.S. commercial expansion and clinical initiatives such as the Bridge Registry to gather real‑world outcomes. The company is privately held and located in Westborough, Massachusetts. Miach Orthopaedics is a privately held company in Westborough, Massachusetts, focused on bio-engineered surgical implants for connective tissue restoration, initially commercializing the BEAR Implant for ACL repair. The BEAR Implant is a bridge-enhanced, bio‑engineered device that, when combined with a small amount of the patient’s blood, facilitates healing of a torn ACL and is resorbed as the ligament heals. The device received De Novo FDA approval in December 2020 and is the first medical technology with Level 1 clinical evidence showing it enables the body to heal a torn ACL. Commercial launch began in fall 2021; more than 500 patients have been treated with the BEAR Implant commercially. The company says the BEAR procedure avoids harvesting or using donor tendon grafts and preserves the ACL’s original attachments. The recent financing will fund ongoing operations and expand the U.S. commercial rollout to bring ACL restoration to more patients. MIACH Orthopaedics is focused on the Bridge-Enhanced® ACL Repair (BEAR®), a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of torn anterior cruciate ligaments. The BEAR technology has been tested in nearly 100 human patients under an FDA Investigational Device Exemption (IDE). Preclinical studies and the company’s clinical work suggest the BEAR procedure avoids graft harvest and may lower long-term arthritis risk versus conventional ACL reconstruction. MIACH plans to use new funding to accelerate manufacturing capabilities and continue U.S. clinical trials of BEAR. The company has received initial research funding from the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. MIACH is a privately held company located in Boston, Massachusetts.